Literature DB >> 7517877

Expression and function of CD59 on colonic adenocarcinoma cells.

L Bjørge1, C A Vedeler, E Ulvestad, R Matre.   

Abstract

The expression and function of CD59, a 19-25 kDa membrane glycoprotein that inhibits formation of the membrane attack complex of complement, was analyzed on normal and malignant human colonic epithelial cells. Analysis by immunofluorescence demonstrated a weak apical expression of CD59 on normal intestinal epithelium, with an increased expression on adenocarcinoma cells. The expression of CD59 was greatest on tumor cells with poor differentiation. The functional activity of CD59 on human adenocarcinoma cells was investigated using the colonic adenocarcinoma cell line HT29. CD59 on HT29 cells was glycosyl-phosphatidylinositol-linked, and had a molecular mass of 19-25 kDa. HT29 cells expressed approximately four times more CD59 than leukocytes, and showed a high resistance to antibody-dependent complement-mediated lysis. Blocking of CD59 with divalent antigen-binding F(ab')2 fragments of the anti-CD59 monoclonal antibody 1F5 resulted in a dose-dependent increase in complement-mediated lysis, suggesting that CD59 may be of importance in protecting colonic adenocarcinoma cells against complement-mediated cytolysis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7517877     DOI: 10.1002/eji.1830240722

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  12 in total

1.  Melanoma cells constitutively release an anchor-positive soluble form of protectin (sCD59) that retains functional activities in homologous complement-mediated cytotoxicity.

Authors:  L I Brasoveanu; E Fonsatti; A Visintin; M Pavlovic; I Cattarossi; F Colizzi; A Gasparollo; S Coral; V Horejsi; M Altomonte; M Maio
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

2.  Protection of human breast cancer cells from complement-mediated lysis by expression of heterologous CD59.

Authors:  J Yu; T Caragine; S Chen; B P Morgan; A B Frey; S Tomlinson
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

3.  Expression of complement regulating factors in gastric cancer cells.

Authors:  T Inoue; M Yamakawa; T Takahashi
Journal:  Mol Pathol       Date:  2002-06

4.  Complement-mediated killing of microtumors in vitro.

Authors:  J Hakulinen; S Meri
Journal:  Am J Pathol       Date:  1998-09       Impact factor: 4.307

5.  Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas.

Authors:  A Mäenpää; S Junnikkala; J Hakulinen; T Timonen; S Meri
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

6.  Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin).

Authors:  G A Niehans; D L Cherwitz; N A Staley; D J Knapp; A P Dalmasso
Journal:  Am J Pathol       Date:  1996-07       Impact factor: 4.307

7.  Human intestinal Vdelta1+ lymphocytes recognize tumor cells of epithelial origin.

Authors:  M J Maeurer; D Martin; W Walter; K Liu; L Zitvogel; K Halusczcak; H Rabinowich; R Duquesnoy; W Storkus; M T Lotze
Journal:  J Exp Med       Date:  1996-04-01       Impact factor: 14.307

8.  Resistance of ovarian teratocarcinoma cell spheroids to complement-mediated lysis.

Authors:  L Bjørge; S Junnikkala; E K Kristoffersen; J Hakulinen; R Matre; S Meri
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

9.  Ascitic complement system in ovarian cancer.

Authors:  L Bjørge; J Hakulinen; O K Vintermyr; H Jarva; T S Jensen; O E Iversen; S Meri
Journal:  Br J Cancer       Date:  2005-03-14       Impact factor: 7.640

10.  Optimizing complement-activating antibody-based cancer immunotherapy: a feasible strategy?

Authors:  Ester Fonsatti; Anna Maria Di Giacomo; Michele Maio
Journal:  J Transl Med       Date:  2004-06-25       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.